talquetamab: gprc5d-cd3 bispecific antibody in r/r myeloma
Published 3 years ago • 547 plays • Length 4:15Download video MP4
Download video MP3
Similar videos
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
2:25
first-in-human study of talquetamab: a gprc5d-cd3 bispecific antibody for r/r mm
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
10:11
monumental-1: talquetamab in r/r multiple myeloma
-
6:58
phase 1 study of the gprc5dxcd3 bispecific talquetamab in patients with rr multiple myeloma
-
3:04
monumental-1 update: talquetamab in r/r multiple myeloma
-
2:47
monumental-1: updated data on talquetamab in r/r myeloma
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
9:25
mgus diagnosis: a step-by-step approach
-
1:05
cinematic rendering animation of an hepatobiliary tumor
-
15:26
the role of venetoclax in myeloma - jonathan kaufman, md | mcrt webcast apr 24, 2021
-
1:10
the importance of bcma, fcrh5 and gprc5d in multiple myeloma
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?
-
2:34
the effect of dose reduction of talquetamab in patients with r/r mm: results from monumental-1
-
2:49
trimm-2 update: talquetamab daratumumab in r/r multiple myeloma
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
1:58
talquetamab and teclistamab in triple-class refractory myeloma: important practical considerations
-
5:38
teclistamab for r/r myeloma
-
10:34
talquetamab - guest lecture
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm